Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Multiple Myeloma Guideline Update 2025
Multiple Myeloma Guideline Update 2025
Shaji Kumar, MD, discusses how the FDA approval of linvoseltamab, a new BCMA-targeted bispecific antibody for relapsed multiple myeloma, expands treatment options with its unique intravenous administration and flexible dosing schedule, while exploring its clinical outcomes, management strategies, and potential for earlier intervention in the disease course.
Videos
Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025Shaji Kumar, MD, Mayo Clinic, discusses the July approval of linvoseltamab, a new bispecific antibody for relapsed myeloma, and how it expands treatment options for patients. He also emphasizes the unique characteristics of linvoseltamab, such as its intravenous administration and flexible dosing schedule.
Read More
